Imatinib-induced eruptive nevi.

Lamiaa Hamie, Rayah Touma Sawaya, Ossama Abbas

Clinical and experimental pharmacology & physiology 2021 Sep

filter terms:

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. It has been associated with a spectrum of pigmentary cutaneous side effects. Despite the well-known association of eruptive melanocytic nevi with the use of other tyrosine kinase inhibitors, this phenomenon has not been linked to the administration of imatinib. We present the first case of imatinib-induced eruptive nevi in an 18-year-old patient with acute lymphocytic leukaemia in remission. © 2021 John Wiley & Sons Australia, Ltd.

Citation

Lamiaa Hamie, Rayah Touma Sawaya, Ossama Abbas. Imatinib-induced eruptive nevi. Clinical and experimental pharmacology & physiology. 2021 Sep;48(9):1298-1299